Penumbra (PEN) Cash from Investing Activities (2014 - 2026)
Penumbra (PEN) posted quarterly Cash from Investing Activities of -$91.1 million for Q2 2026, down 484.67% year-over-year from $23.7 million in Q2 2025, and down 197.36% quarter-over-quarter from -$30.6 million in Q1 2026.
Penumbra (PEN) Cash from Investing Activities (2014 - 2026) Analysis & Trends
Penumbra (PEN) has reported Cash from Investing Activities for 13 consecutive years, with -$91.1 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Cash from Investing Activities fell 484.67% year-over-year to -$91.1 million; the TTM figure through Jun 2026 stood at -$510.2 million (down 5975.54% YoY), while the FY2025 annual figure was -$404.6 million, down 621.22% from the prior year.
- Cash from Investing Activities fell to -$91.1 million in Q2 2026 per PEN's latest filing, from -$30.6 million in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $35.7 million in Q3 2024 and bottomed at -$225.6 million in Q4 2025.
- Historically, Cash from Investing Activities has averaged -$22.8 million across 5 years, with a median of $4.1 million in 2022.
- Annual changes were most pronounced in 2022 — Cash from Investing Activities surged 744.73% — and 2026, when it tumbled 6002.19%.
- Penumbra's Cash from Investing Activities stood at $8.6 million in 2022, then jumped by 181.25% to $24.3 million in 2023, then tumbled by 145.12% to -$11.0 million in 2024, then slumped by 1959.76% to -$225.6 million in 2025, then surged by 59.63% to -$91.1 million in 2026.
- Business Quant data shows PEN's Cash from Investing Activities at -$91.1 million in Q2 2026, -$30.6 million in Q1 2026, and -$225.6 million in Q4 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.70 Bn | 193.10 Bn | 7.27 Bn | -673.00 Mn |
| 2 | Stryker | 125.85 Bn | 122.37 Bn | 4.50 Bn | -639.00 Mn |
| 3 | Medtronic | 118.44 Bn | 109.22 Bn | 6.41 Bn | -917.00 Mn |
| 4 | Boston Scientific | 72.64 Bn | 72.10 Bn | 3.85 Bn | -1.96 Bn |
| 5 | Edwards Lifesciences | 51.94 Bn | 47.69 Bn | 1.35 Bn | -193.20 Mn |
| 6 | Dexcom | 34.48 Bn | 32.53 Bn | 830.00 Mn | 329.80 Mn |
| 7 | GE HealthCare Technologies | 33.60 Bn | 31.49 Bn | 2.18 Bn | -115.00 Mn |
| 8 | Koninklijke Philips | 26.30 Bn | 22.98 Bn | 4.55 Bn | -22.08 Mn |
| 9 | Steris | 23.00 Bn | 22.52 Bn | 684.20 Mn | -108.50 Mn |
| 10 | Penumbra | 12.76 Bn | 12.10 Bn | 264.94 Mn | -91.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -91.09 Mn |
| Jun 30, 2026 | -91.09 Mn |
| Mar 31, 2026 | -30.63 Mn |
| Mar 31, 2026 | -30.63 Mn |
| Dec 31, 2025 | -225.65 Mn |
| Dec 31, 2025 | -225.65 Mn |
| Sep 30, 2025 | -162.86 Mn |
| Sep 30, 2025 | -162.86 Mn |
| Jun 30, 2025 | -15.58 Mn |
| Jun 30, 2025 | -15.58 Mn |
| Mar 31, 2025 | -502,000.00 |
| Mar 31, 2025 | -502,000.00 |
| Dec 31, 2024 | -10.96 Mn |
| Dec 31, 2024 | -10.96 Mn |
| Sep 30, 2024 | 35.72 Mn |
| Sep 30, 2024 | 35.72 Mn |
| Jun 30, 2024 | 34.47 Mn |
| Jun 30, 2024 | 34.47 Mn |
| Mar 31, 2024 | 18.38 Mn |
| Mar 31, 2024 | 18.38 Mn |